Abstract
The HER2 gene encodes a tyrosine kinase receptor overexpressed in 25–30% of human breast cancers. Clinical trials have shown the efficacy of the anti-HER2 monoclonal antibody Trastuzumab in metastatic breast cancer patients. Nevertheless, 70% of patients are unresponsive from start of treatment and nearly all become unresponsive during treatment. Possible mechanisms for these failures could depend on impairment of the machinery responsible for receptor downregulation. To test this hypothesis, we analysed the genomic sequences encoding regions known to be critical for HER2 downregulation, of both HER2 and of the ubiquitin ligase Cbl. We investigated 63 breast cancers, and found no mutations in these regions. We thus considered alternative mechanisms – such as TGFα production – possibly interfering with HER2 downregulation. In selected cases, by comparing breast cancer neoplastic tissue before and after Trastuzumab treatment, we found induction of TGFα expression. Moreover, by in vitro expression of exogenous TGFα in breast cancer cells, we observed a dramatic reduction in Trastuzumab-induced HER2 endocytosis, downregulation and cell growth inhibition. Our results suggest that unresponsiveness to Trastuzumab may not be due to intrinsic defects in the machinery responsible for HER2 downregulation, but can be associated with a TGFα-related mechanism of escape to HER2 downregulation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alwan HA, Van Zoelen EJ and Van Leeuwen JE . (2003). J. Biol. Chem., 278, 35781–35790.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ . (1999). J. Clin. Oncol., 17, 2639–2648.
Conner SD and Schmid SL . (2003). Nature, 422, 37–44.
Cooley S, Burns LJ, Repka T and Miller JS . (1999). Exp. Hematol., 27, 1533–1541.
Dikic I and Giordano S . (2003). Curr. Opin. Cell Biol., 15, 128–135.
Ebner R and Derynck R . (1991). Cell. Regul., 2, 599–612.
Graus-Porta D, Beerli RR, Daly JM and Hynes NE . (1997). EMBO J., 16, 1647–1655.
Johannes L and Lamaze C . (2002). Traffic, 3, 443–451.
Klapper LN, Waterman H, Sela M and Yarden Y . (2000). Cancer Res., 60, 3384–3388.
Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP and Chinnaiyan AM . (2003). Cancer Res., 63, 132–139.
Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ and Yarden Y . (1998). EMBO J., 17, 3385–3397.
Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M and Yarden Y . (1995). Oncogene, 12, 1117–1125.
Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M and Yarden Y . (2000). J. Biol. Chem., 45, 35532–35539.
Leyland-Jones B . (2002). Lancet Oncol., 3, 137–144.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA . (2004). N. Engl. J. Med., 350, 2129–2139.
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J and Baselga J . (2001). Cancer Res., 61, 4744–4749.
Muller WJ, Arteaga CL, Muthuswamy SK, Siegel PM, Webster MA, Cardiff RD, Meise KS, Li F, Halter SA and Coffey RJ . (1996). Mol. Cell. Biol., 16, 5726–5736.
Muthuswamy SK, Gilman M and Brugge JS . (1999). Mol. Cell. Biol., 19, 6845–6857.
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC and Yu D . (2004). Cancer Cell, 6, 117–127.
Nichols BJ and Lippincott-Schwartz J . (2001). Trends Cell Biol., 11, 406–412.
Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS and Menard S . (2002). Ann. Oncol., 13, 65–72.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M . (2004). Science, 304, 1497–1500.
Rabouille C . (1999). Methods Mol. Biol., 117, 125–144.
Shah NP and Sawyers CL . (2003). Oncogene, 22, 7389–7395.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L . (2001). N. Engl. J. Med., 344, 783–792.
Sorkin A and Waters CM . (1993). Bioessays, 15, 375–382.
Tacchetti C, Quarto R, Nitsch L, Hartmann DJ and Cancedda R . (1987). J. Cell Biol., 105, 999–1006.
Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB and Grogan TM . (2001). J. Clin. Oncol., 19, 2714–2721.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M . (2002). J. Clin. Oncol., 20, 719–726.
Wiley HS and Burke PM . (2001). Traffic, 2, 12–18.
Yarden Y and Sliwkowski MX . (2001). Nat. Rev. Mol. Cell. Biol., 2, 127–137.
zum Büschenfelde CM, Hermann C, Schmidt B, Peschel C and Bernhard H . (2002). Cancer Res., 62, 2244–2247.
Acknowledgements
We thank S Gutkind for kindly providing TGFα cDNA; L Naldini for providing the p156RRLsinPPThCMVMCSpre lentiviral vector; L Granziero for help in flow cytometry studies; L Tamagnone and our colleagues for helpful discussions; A Cignetto for secretarial assistance; and E Wright for editing the manuscript. The technical assistance of L Palmas, R Albano and F Grasso is acknowledged. This work was supported by MURST COFIN to SG, AIRC Grants to SG, PMC and CT, and FIRC Grant to CT.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Valabrega, G., Montemurro, F., Sarotto, I. et al. TGFα expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 24, 3002–3010 (2005). https://doi.org/10.1038/sj.onc.1208478
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208478
Keywords
This article is cited by
-
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
BMC Cancer (2018)
-
Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
Nature Communications (2018)
-
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Experimental Hematology & Oncology (2017)
-
Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
Journal of Cancer Research and Clinical Oncology (2017)
-
Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability
Journal of Pharmacokinetics and Pharmacodynamics (2017)